Hong Kong Exchanges & Clearing Third-Quarter Profit Rose 30% — Update
By Sherry Qin
Hong Kong Exchanges & Clearing's third-quarter net profit saw steady growth, supported by higher net investment income.
The exchange operator said on Friday that its third-quarter net profit grew 30% compared with the same period a year earlier to 2.95 billion Hong Kong dollars (US$377.1 million). That compared with a 31% on year increase in the first half of the year.
Core revenue rose 9% to HK$4.70 billion in the third quarter, it said, thanks to increased net investment income, though it was partially offset by lower listing fees. HKEX's listing fees for equity products decreased by HK$66 million, mainly due to a fall in the number of forfeitures, it said. The headline average daily turnover edged 1% higher to HK$98.4 billion.
"The macro backdrop remains fragile, but the business is in good shape and is well-positioned to capitalize on slowly improving market sentiment," Chief Executive Nicolas Aguzin said in a statement.
HKEX raised HK$24.6 billion with 47 new listings in the first nine months of the year, down 67% on year, and attributed it to the overall weakness in the global market for initial public offerings.
However, HKEX's IPO pipeline remained strong, with 115 active applications as at Sept. 30, it said. Going into the fourth quarter there are early signs of renewed activity in the global fund-raising market, it added.
Write to Sherry Qin at sherry.qin@wsj.com
(END) Dow Jones Newswires
October 20, 2023 00:52 ET (04:52 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth